HUYABIO International
12531 High Bluff Drive
Suite 138
San Diego
California
92130
United States
Website: https://huyabio.com/
About HUYABIO International
HUYABIO has now grown to be the leader in globalizing China’s pharmaceutical innovation. Meeting the challenge of tomorrow’s unmet medical needs requires utilizing the talents of Chinese researchers and helping to move their discoveries forward. Our HUYABIO teams in San Diego, Tokyo, Dublin, Montreal, Seoul and our eight China offices are committed to building relationships that enable candidate compounds to be more accessible internationally. With diverse approaches including in-licensing, alliances, co-development, research funding and creative financial partnerships, HUYABIO is poised to bring China’s healthcare discoveries to benefit the rest of the world.
When joining us at HUYABIO, you become part of the team, right here and now. Where you are empowered to lead and perform at your best. Where you collaborate across disciplines, borders, and continents. HUYABIO International is committed to creating a diverse environment and is proud to be an equal opportunity employer.
86 articles with HUYABIO International
-
Genentech has partnered with Jemincare to develop and commercialize an asset that may provide new treatment options for people with advanced-stage prostate cancer.
-
HUYABIO INTERNATIONAL ANNOUNCES INITIATION OF HBI-3000 PHASE 2 TRIAL
6/14/2022
HUYABIO International today announced that the first three patients had been dosed in an ongoing Phase 2 study of HUYABIO's novel drug for pharmacological cardioversion of atrial fibrillation (AF).
-
HUYABIO INTERNATIONAL ANNOUNCES COMPLETION OF HBI-3000 PHASE 1 TRIAL AND FDA APPROVAL TO PROCEED WITH DOSE ESCALATION IN PHASE 2
5/17/2022
Phase 1 trial evaluated the pharmacokinetics and safety of HBI-3000 when dosed with the strong CYP2D6 inhibitor, paroxetine.
-
HUYABIO Announces the Exclusive License of the KRAS Inhibitor from Shanghai Jemincare Pharmaceutical
12/2/2021
HUYABIO International, the leader in accelerating global development of China's pharmaceutical innovations, announced today it had licensed exclusive worldwide ex-China rights to the KRAS inhibitor, JMKX1899, from Shanghai Jemincare Pharmaceutical Co., Ltd. Jemincare will retain the relevant rights in the greater China area.
-
Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan
12/1/2021
Shenzhen Chipscreen Biosciences' licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Chidamide (Tucidinostat, also known as Epidaza ®, Hiyasta®, HBI-8000) monotherapy for the treatment of relapsed or refractory (R/R) PTCL by the Ministry of Health, Labour and Welfare in Japan.
-
Jemincare Announces the Exclusive License of the Kras Inhibitor to HUYABIO
11/30/2021
Jemincare, a leading pharmaceutical company from China, announced its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., had licensed exclusive worldwide ex-China rights to the Kras inhibitor, JMKX1899, to HUYABIO International, the leader in accelerating global development of China's pharmaceutical innovations.
-
HUYABIO International Receives Regulatory Approval For Hiyasta® Monotherapy Of Peripheral T-Cell Lymphoma In Japan
11/30/2021
HUYABIO International, the leader in accelerating global development of China's pharmaceutical innovations, today announced the regulatory approval of HBI-8000, brand name Hiyasta®, monotherapy for the treatment of relapsed or refractory (R/R) PTCL by the Ministry of Health, Labour and Welfare in Japan.
-
HUYABIO Announces the Exclusive License of the Wee1 Inhibitor from Shanghai Pharmaceuticals
11/9/2021
HUYABIO International, the leader in accelerating global development of China's pharmaceutical innovations, announced it had licensed exclusive worldwide ex-China rights to the Wee1 inhibitor from Shanghai Pharma, the second largest pharma group in China with annual sales of over $30 billion.
-
HUYABIO Announces FDA Clearance to Initiate a Phase 1 Trial of SHP2 Inhibitor in Patients with KRAS and EGFR Mutated Tumors
10/28/2021
HUYABIO International announced today the FDA clearance of HBI-2376 as an Investigational New Drug, or IND, for a Phase 1 study.
-
HUYABIO International Launches Hiyasta as Monotherapy for Adult T-cell Leukemia/Lymphoma in Japan
10/19/2021
HUYABIO International (HUYABIO™), the leader in accelerating global development of China's pharmaceutical innovations, today announced the product launch in Japan for Hiyasta® tablets to treat relapsed and/or refractory (R/R) adult T-cell leukemia/lymphoma (ATLL).
-
HUYABIO Announces First Patient Treated in a Pivotal Study of HBI-8000 Combined with Opdivo® (nivolumab) in Patients with Advanced Melanoma
9/21/2021
HUYABIO International announced today the first patient treated in a pivotal trial designed to measure the safety and efficacy of HBI-8000 combined with Bristol Myers Squibb's anti-PD-1, antibody Opdivo ®
-
HUYABIO Files an Investigational New Drug Application with the FDA for the Novel SHP2 Inhibitor HBI-2376
8/31/2021
HUYABIO International announced today the filing of an investigational new drug application (IND) with the FDA for HBI-2376 along with Genhouse who has filed an IND with the Chinese Center for Drug Excellence CDE.
-
Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan
6/24/2021
Shenzhen Chipscreen Biosciences' licensing partner, HUYABIO International, announced the regulatory approval for Tucidinostat monotherapy of relapsed or refractory adult T-cell leukemia/lymphoma by the Japanese Pharmaceuticals and Medical Devices Agency.
-
HUYABIO Announces HBI-8000 Brand Name of Hiyasta™
6/24/2021
HUYABIO International announced today that HBI-8000 will be marketed under the brand name Hiyasta ™ in Japan .
-
HUYABIO International Receives Regulatory Approval for HBI-8000 Monotherapy of Adult T-cell Leukemia/Lymphoma in Japan
6/23/2021
HUYABIO International (HUYABIO™), the leader in accelerating global development of China's pharmaceutical innovations, today announced the regulatory approval for HBI-8000 monotherapy of relapsed or refractory (R/R) adult T-cell leukemia/lymphoma (ATL) by the Japanese Pharmaceuticals and Medical Devices Agency.
-
HUYABIO International Submits HBI-8000 Monotherapy for Peripheral T-cell Lymphoma for Regulatory Approval in Japan
4/6/2021
HUYABIO International (HUYABIO™), the leader in accelerating global development of China's pharmaceutical innovations, today announced the submission of a regulatory application to the Japanese Pharmaceuticals and Medical Devices Agency for HBI-8000 monotherapy for relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL).
-
Huyabio International Announces Global Clinical Trial Collaboration With Bristol Myers Squibb In Melanoma
3/30/2021
HUYABIO International (HUYABIO™), the leader in accelerating global development of China's pharmaceutical innovations, today announced that it had entered into a clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY) to evaluate the combination of HUYABIO's HBI-8000, an epigenetic immunomodifier, and Opdivo® (nivolumab), a PD-1 blocking antibody
-
HUYABIO International And Tianjin Institute of Pharmaceutical Research Joint venture Submits Chinese New Drug Application For efinaconazole as Jublia™
3/9/2021
HUYABIO International (HUYABIO), the leader in accelerating global development of China's pharmaceutical innovations, today announced that its joint venture with Tianjin Institute of Pharmaceutical Research has submitted a New Drug Application to the Chinese National Medical Products Administration's Center for Drug Evaluation.
-
HUYA Bioscience International Presents Positive Data On HBI-8000 at Society for Immunotherapy of Cancer Meeting
11/9/2020
HUYA Bioscience International (HUYABIOTM), the leader in accelerating global development of China's pharmaceutical innovations, today announced the presentation of results from an ongoing Phase II study evaluating the efficacy and safety of HBI-8000 in combination with nivolumab in patients with advanced metastatic melanoma
-
HUYA Bioscience International Submits HBI-8000 Monotherapy for Adult T-cell Leukemia/Lymphoma for Regulatory Approval in Japan
10/6/2020
HUYA Bioscience International (HUYABIOTM ), the leader in accelerating global development of China's pharmaceutical innovations, today announced the submission of a regulatory application to the Japanese Pharmaceuticals and Medical Devices Agency for HBI-8000 monotherapy for relapsed or refractory (R/R) adult T-cell leukemia/lymphoma (ATL).